Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Public Venture Capital for Israel's Biotech Industry

This article was originally published in Start Up

Executive Summary

Israeli biotech is hot -- lots of ideas and lots of entrepreneurs. But the industry is chronically short of management and venture money. For the latter, companies have turned to Israel's recently deregulated stock market.

Related Content

Xenia's Public-Private Blend Fosters Early-Stage Medtech
The Existential Dilemma of Israeli Biotech
Mixed Blessing: Teva and Israeli Biotech
Medical Device and In Vitro Diagnostics Deal Statistics Quarterly, Q3 2007
Obecure Ltd.
The New Device Incubators
Overheard at JP Morgan's 25th Health Care Conference: Making Up for Lost Drugs: Pharma Attempts to Appease Investors
Synosis: the Financial Leverage of Translational Medicine
Israel, Fertile Land for Device Company Creation
Germany's Biotech Boomlet


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts